# Retatrutide References: Full Citation List with DOIs and PubMed Links

> Complete retatrutide reference list — Phase 1b and Phase 2 trial publications, structural biology, kidney outcomes data, and Phase 3 trial registrations with DOIs and PubMed URLs.

Every source cited across this site — numbered, with DOI and PubMed link where available.

## Retatrutide references

All citations used across this site are listed below, numbered to match inline citations [1]–[15]. DOIs and PubMed/PMC URLs are provided for every entry where available.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Function. ClinicalTrials.gov. 2024. NCT06383390. https://clinicaltrials.gov/study/NCT06383390
[8] Bailey CJ, et al. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025;187:171380. https://doi.org/10.1016/j.peptides.2025.171380
[9] Kokkorakis M, et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacological Reviews. 2025;77(1):100002. https://doi.org/10.1124/pharmrev.123.001045
[10] The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. https://pubmed.ncbi.nlm.nih.gov/39724554/
[11] The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes or Overweight/Obesity. Kidney Int Rep. 2025. https://pubmed.ncbi.nlm.nih.gov/40630318/
[12] Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide. Nephrol Dial Transplant. 2025. https://pubmed.ncbi.nlm.nih.gov/41160422/
[13] Pillai AA, et al. Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review. Cardiology in Review. 2026. https://doi.org/10.1097/CRD.0000000000001310
[14] Pallavi K, et al. Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis. Maedica. 2025. https://doi.org/10.26574/maedica.2025.20.4.824
[15] Appetite, eating attitudes, and eating behaviours during treatment with retatrutide. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/40916752/

---

A blueprint-level reading of the published retatrutide trial record — Phase 2 figures logged to source, the kidney and cardiac questions marked open, and no clinic, prescription, or product behind the drafting sheet.